Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.
The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.
Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.
The European Commission approval for trastuzumab deruxtecan in HER2-low metastatic breast cancer is based on data from the phase 3 DESTINY-Breast04 trial.
Adjuvant chemotherapy following multiagent neoadjuvant chemotherapy and surgical resection produced better overall survival among patients with pancreatic ductal adenocarcinoma vs those who did not receive adjuvant treatment.
The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.
Tamibarotene is a first-in-class oral first-in-class selective retinoic acid receptor α agonist that is being evaluated in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome.